Wasatch Funds gathers its best ideas in this top-performing global mutual fund. Read More

There are lots of reasons to be upset with Facebook and its CEO Mark Zuckerberg, but its recent decision to buy back $1.92 billion in stock is not one of them. Read More

Investors are debating what Chevron should do with the record amount of cash on its balance sheet. But management is keeping quiet. Read More

With critical meetings of the European Central Bank and the U.S. Federal Reserve scheduled to take place during the first half of September, stock-market volatility is bound to increase. Read More

U.S. energy royalty trusts have been great income investments over the past decade, but buying high yields at prices above underlying asset value can be dangerous to your wealth. Read More

Investing Daily's investment experts share some intimate details about their investment firsts and what lessons they learned. Read More

Gilead Sciences (NasdaqGS: GILD) may lead the race to offer an all-oral treatment for Hepatitis C liver disease, but several other drug companies are also in the hunt. Read More

The stock market is near four-year highs, but that hasn't stopped some stocks from plunging. Jim discusses three such stocks, only one of which is a speculative buy. Read More

Although there are numerous investment products designed to exploit the VIX, their long-term price trajectory is toward zero. Read More

August means 13F filing season, which allows us to peek into the minds of the world's greatest investors. Consumer staples and technology are in, while Citigroup is out. Read More